{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:45:36Z","timestamp":1790959536676,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Lymphocytes are effector cells that fight cancer by killing tumor cells. Here, we aim to explore the prognostic significance of both peripheral and tumor-infiltrating lymphocytes (TILs) in newly diagnosed stage III\/IV non-small-cell lung cancer (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>In total, 105 cases of newly diagnosed stage III\/IV NSCLC from July 2017 to October 2022 at the Tianjin Beichen Hospital were retrospectively investigated. Peripheral blood samples at the time of diagnosis and tumor tissue slices from these patients were collected. General peripheral blood cell composition and TILs were measured and analyzed via an automatic blood analyzer and immunofluorescence staining analysis. The overall survival (OS) time of all patients was also obtained and analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median overall survival (mOS) of all patients is 12\u2009months. The 1-, 2-, and 3-year overall survival rates were 60.5, 28.4, and 18.6%, respectively. Peripheral lymphocyte and neutrophil percentages, serum C-reactive protein (CRP) expression, tumor size, and tumor pathology are the prognostic factors of OS for newly diagnosed stage III\/IV NSCLC patients. Moreover, patients with high tumor CD4+ and CD8+ T cell infiltration survived significantly longer compared to patients with low tumor CD4+ and CD8+ T cell infiltration (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001 and <jats:italic>p<\/jats:italic>\u2009=\u20090.011, respectively). Compared to low tumor CD33+ cell infiltration, high tumor CD33+ cell infiltration was associated with worse OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.018). High tumor CD8+ T cell infiltration was associated with lower peripheral lymphocyte number, lower serum CRP expression, smaller tumor size, and better tumor pathology (<jats:italic>p<\/jats:italic>\u2009=\u20090.012, <jats:italic>p<\/jats:italic>\u2009=\u20090.040, <jats:italic>p<\/jats:italic>\u2009=\u20090.012, and <jats:italic>p<\/jats:italic>\u2009=\u20090.029, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Increased numbers of peripheral lymphocytes, CD33+ cells, CD4+ TILs, and CD8+ TILs were significantly associated with OS in newly diagnosed stage III\/IV NSCLC patients, which were positively associated with several basic clinical factors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1349178","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T04:52:31Z","timestamp":1716353551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III\/IV non-small-cell lung cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Fenge","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huancheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengli","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of\u2002cancer\u2002immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/cac2.12178","article-title":"Advancing to the era of\u2002cancer\u2002immunotherapy","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e000705","DOI":"10.1136\/jitc-2020-000705","article-title":"SITC\u2002cancer\u2002immunotherapy\u2002resource document: a compass in the land of biomarker discovery","volume":"8","author":"Hu-Lieskovan","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e002449","DOI":"10.1136\/jitc-2021-002449","article-title":"Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma","volume":"9","author":"Saberian","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1 resistant metastatic lung cancer: a phase I trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1018786","DOI":"10.3389\/fimmu.2022.1018786","article-title":"CAR-T cell therapy in triple-negative breast cancer: hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1070353","DOI":"10.3389\/fonc.2022.1070353","article-title":"Innovation in BCMA\u2002CAR-T therapy: building beyond the model T","volume":"12","author":"Banerjee","year":"2022","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"896242","DOI":"10.3389\/fimmu.2022.896242","article-title":"Process development for adoptive cell\u2002therapy\u2002in academia: a pipeline for clinical-scale manufacturing of multiple\u2002TCR-T\u2002cell products","volume":"13","author":"Silva","year":"2022","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8345235","article-title":"Tils and anti-Pd1 therapy: an alternative combination therapy for Pdl 1 negative metastatic cervical cancer","volume":"2020","author":"Yin","year":"2020","journal-title":"J Immunol Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (Ln-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"Am Soc Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-022-02340-2","article-title":"The role of tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.21.02170","article-title":"Breast cancers are immunogenic: immunologic analyses and a phase ii pilot clinical trial using mutation-reactive autologous lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00262-015-1715-3","article-title":"Phase I\/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer","volume":"64","author":"Zhen","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/cancers13040781","article-title":"Prognostic significance of Cd4+ and Cd8+ tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: a meta-analysis","volume":"13","author":"Borsetto","year":"2021","journal-title":"Cancers"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-020-6668-z","article-title":"Prognostic value of\u2002tumor-infiltrating lymphocytes\u2002in patients with triple-negative breast cancer: a systematic review and meta-analysis","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.3390\/cancers14215332","article-title":"Tumor-infiltrating lymphocytes\u2002(TILs) in epithelial ovarian Cancer: heterogeneity, prognostic impact, and relationship with immune checkpoints","volume":"14","author":"Hudry","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"7227","DOI":"10.18632\/oncotarget.6979","article-title":"Prognostic\u2002value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA (N2) non-small cell\u2002lung cancer","volume":"7","author":"Feng","year":"2016","journal-title":"Oncotarget"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"13765","DOI":"10.18632\/oncotarget.7282","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer","volume":"7","author":"Zeng","year":"2016","journal-title":"Oncotarget"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12672-023-00615-4","article-title":"Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer","volume":"14","author":"Kaira","year":"2023","journal-title":"Discov Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/02184923211042129","article-title":"Prognostic impact of tumor-infiltrating lymphocytes in non-small cell lung carcinomas","volume":"30","author":"Mlika","year":"2022","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"633205","DOI":"10.3389\/fimmu.2021.633205","article-title":"Natural killer cell interactions with\u2002myeloid derived suppressor cells\u2002in the tumor microenvironment and implications for cancer immunotherapy","volume":"12","author":"Zalfa","year":"2021","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"640131","DOI":"10.3389\/fonc.2021.640131","article-title":"A retrospective study on using a novel single needle cone puncture approach for the Iodine-125 seed brachytherapy in treating patients with thoracic malignancy","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"830631","DOI":"10.3389\/fimmu.2022.830631","article-title":"Checkpoint inhibitor pneumonitis induced by anti-PD-1\/PD-L1 therapy in non-small-cell\u2002lung cancer: occurrence and mechanism","volume":"13","author":"Yin","year":"2022","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1\u2002blockade\u2002therapy in advanced non-small-cell\u2002lung cancer: current status and future directions","volume":"24","author":"Xia","year":"2019","journal-title":"Oncologist"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cac2.12244","article-title":"Anti-PD-L1\/TGF-\u03b2R fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced\u2002resistance\u2002to PD-1\/PD-L1 inhibitors in\u2002lung cancer","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun (Lond)."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fimmu.2019.00071","article-title":"Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1002\/mco2.213","article-title":"High post-chemotherapy\u2002TIL\u2002and increased CD4+TIL\u2002are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy","volume":"4","author":"Jia","year":"2023","journal-title":"Med Comm"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/cancers15041164","article-title":"Clinical significance of tumour-infiltrating B lymphocytes (TIL-Bs) in breast cancer: a systematic literature review","volume":"15","author":"Lam","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"731329","DOI":"10.3389\/fimmu.2021.731329","article-title":"Prognostic landscape of tumor-infiltrating T and B cells in human Cancer","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1349178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T04:52:35Z","timestamp":1716353555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1349178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":30,"alternative-id":["10.3389\/fmed.2024.1349178"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1349178","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"article-number":"1349178"}}